Harris Corporation (NYSE:HRS), an international communications and information technology company, has been awarded a $37 million recompete contract by the National Cancer Institute's Center for Cancer Research (NCI CCR). The contract, which includes one base year and four one-year options, continues Harris' twenty-nine year legacy of providing comprehensive clinical data management for the National Cancer Institute's intramural clinical trials program.
“Harris will continue to evolve and implement enhanced processes, procedures, training, and technologies to deliver accurate, timely clinical data management support in full compliance with federal regulations.”
Under the contract, Harris will continue to provide the expertise that has consistently enabled increased data volume capacity and upheld high data quality within funding expectations under past contracts. Specific tasks include clinical data management, quality assurance and control, clinical audit and monitoring of clinical trials for safety and compliance, and maintenance and enhancement of research databases and systems.
"The Harris team has consistently delivered increased data accuracy and improved program efficiencies over its twenty-nine years of experience with the National Cancer Institute," said Dan Pearson, executive vice president and chief operating officer, Harris Corporation. "Harris will continue to evolve and implement enhanced processes, procedures, training, and technologies to deliver accurate, timely clinical data management support in full compliance with federal regulations."
The Harris team includes subcontractor Asclepius Solutions, Inc., and is comprised of medical doctors, research professionals, and IT specialists. This contract was awarded under the National Institutes of Health's CIO-SP2i government-wide acquisition contract vehicle.
Researchers uncover key genes linked to DCIS progression